As I promised, I’m doing some deep dives into the research and claims around GLP-1 agonist drugs for actual health uses other than their use in managing Type 2 Diabetes. For this series, I’ll be doing the deep dives as well as analyzing the studies using the framework that I discussed here.
Kidney-related health is one of the claimed uses I’m most often asked about with GLP1s, that providers have told me they feel is one of the most promising, and which recently received FDA approval (for semaglutide), so I’m going to start there. I want to reiterate that while I have serious questions about the safety and efficacy (especially long-term of the drugs for intentional weight loss, they are solid Type 2 Diabetes drugs and they may have other health benefits.
